Laurus Labs Q3 FY26: Revenue up 26%, Net Profit jumps 174% YoY
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts more than Nifty Midcap 150 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Laurus Labs reported strong Q3 FY26 results with revenues of ₹1,778 Cr, up 26% YoY. 9M FY26 revenues reached ₹5,001 Cr, up 30% YoY. EBITDA surged 70% to ₹485 Cr in Q3, with margins expanding to 27.3%. 9M EBITDA doubled to ₹1,303 Cr at 26.1% margins, a 9.5 point gain. Net profit jumped 174% to ₹252 Cr in Q3 and 388% to ₹610 Cr for 9M. Gross margins improved 4.3 points to 60.1%. Generics division drove growth at 37% YoY in Q3, while CDMO small molecules grew 50% in 9M. Net debt leverage fell to 1.2x EBITDA.
Strong revenue, profit growth and margin expansion signal robust momentum; positive for shareholders and stock outlook.